Pay in 4 interest-free payments of $6.10 Learn more
Ships within 48 hours · Estimated delivery Aug 12 - Aug 17
Partner Pharmacies Licensed pharmacies compound and dispense medications based on valid prescriptions
Dual GIP/GLP-1 agonists now represent the highest-revenue growth segment in the GLP-1 weight loss drug market at 18.4% CAGR , with tirzepatide generating USD 18.3 billion in 2025 revenue through Zepbound and Mounjaro surpassing Eli Lillys entire insulin franchise within two years of commercial launch
Clinical studies show that patients using semaglutide lose significantly more weight than those on diet and exercise alone, with many achieving sustained results over 12 months or longer
Following a cycle, a 2-4 week break is advised to help resensitize growth hormone receptors
Missed doses If a dose is missed, resume as prescribed at the next scheduled dose
Wegovy is recommended by NICE within specialist NHS services for up to two years, whereas Saxenda has more limited and variable NHS commissioning with availability depending on local decisions
.png)
